4 November 2021
Riber’s revenue grows 10% in Q3 to €6.6m
For the nine months to end-September, Riber S.A. of Bezons, France – which manufactures molecular beam epitaxy (MBE) systems as well as evaporation sources and effusion cells – has reported revenue down 9% year-on-year from €17.5m to €15.8m. This included Services & Accessories revenue up 5% from €7.9m to €8.2m, but Evaporators flat at just €0.1m (due to the continuing lack of investment in OLED screen production equipment) and MBE Systems sales down by 22% from €9.5m to €7.5m (reflecting the seasonality of the delivery schedule, focused on second-half 2021).
By geographic region, 45% came from Asia (up from 32% in the first nine months of 2020), 48% came from Europe (up from 44%) and just 7% came from North America (down from 24%).
However, most of the contraction in revenue occurred in first-quarter 2021 (down 41% year-on-year, from €5.4m to €3.2m).
In contrast, revenue for third-quarter 2021 was €6.6m, up 10% on €6m in Q2/2021 and 11% on €5.9m a year ago.
Riber notes that its commercial turnaround measures rolled out over the year have continued to deliver benefits. During Q3/2021, Riber recorded orders for one production system and two research systems (including the order announced on 4 October), while further strengthening its Services & Accessories business.
Riber’s order book grew by 16.7% in Q3/2021 from €17.4m to €20.3m at the end of September, up 12% on €18.2m a year previously. This was due to MBE Systems orders growing by 45% year-on-year from €8.6m to €12.6m (comprising six systems to be delivered in 2021, including two production systems, as well as one research system to be delivered in 2022). Orders for Services & Accessories were down 19% to €7.7m, but this from a higher-than-usual €9.6m a year previously.
Riber says that, in view of the industrial production schedule for fourth-quarter 2021, it can confirm its full-year 2021 forecast for revenue of over €30m and operating income of €1.2m.